Ubs Asset Management Americas Inc Supernus Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $477 Billion
- Q2 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 167,692 shares of SUPN stock, worth $8.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
167,692
Previous 107,789
55.57%
Holding current value
$8.1 Million
Previous $3.53 Million
49.72%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding SUPN
# of Institutions
312Shares Held
61.7MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$502 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$300 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$232 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$146 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$133 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.58B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...